$1.33
Today
as of Jul 22, 16:51 ET
Last 30 days
Recent Press Releases & News
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova CEO Provides Shareholder Update
MediciNova Granted US Patent Notice of Allowance for Ibudilast Combination to Treat Brain Cancer
Overview
52-week range
$1.17
$1.96
20% of range
Avg surprise (last 2)
+8.3%
Avg reaction (last 2)
+1.8%
100% positive
Latest IV / EM
1252%
EM ±165.4% · $3 · Jun 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 14, 2026 | Mar/2026 | $-0.05 | $-0.06 | +16.7% | +16.7% | +2.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.06 | — | — | — | — | financials |
| Thu Aug 14, 2025 | Jun/2025 | $-0.07 | $-0.07 | 0.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.06 | — | — | — | +1.4% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.05 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.06 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.06 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 13, 2026 | Jun/2026 | OTHER | -$0.06 | -$0.07 | +14.3% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-3M | — | $-3M | $-4M | $-3M | — | $-3M | $-3M |
| Net income | $-3M | — | $-3M | $-3M | $-3M | — | $-3M | $-3M |
| EPS (diluted) | $-0.05 | — | $-0.06 | $-0.07 | $-0.06 | — | $-0.06 | $-0.05 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $27M | $31M | $33M | $34M | $37M | $40M | $42M | $44M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $28M | $31M | $33M | $35M | $38M | $41M | $43M | $46M |
| Total assets | $43M | $46M | $48M | $50M | $52M | $56M | $58M | $60M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $3M | $4M | $4M | $3M | $3M | $3M | $3M | $3M |
| Total equity | $39M | $42M | $44M | $47M | $50M | $53M | $55M | $57M |